Avalyn Pharma Inc.
For the period ended Mar 31, 2026. Filed Jun 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Jun 3, 2026
AVLN$31.17+5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income (Loss)
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except share and per share amounts) (Unaudited)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| OPERATING EXPENSES: | ||
| Research and development | $22,889 | $15,319 |
| General and administrative | 5,020 | 3,397 |
| Total operating expenses | 27,909 | 18,716 |
| LOSS FROM OPERATIONS | (27,909) | (18,716) |
| OTHER INCOME (EXPENSE): | ||
| Interest income | 1,125 | 1,248 |
| Interest expense | (98) | — |
| Other income (expense) | 13 | (35) |
| Total other income | 1,040 | 1,213 |
| NET LOSS | $(26,869) | $(17,503) |
| COMPREHENSIVE LOSS: | ||
| Net loss | $(26,869) | $(17,503) |
| OTHER COMPREHENSIVE INCOME: | ||
| Unrealized losses on marketable securities | (122) | (88) |
| Total other comprehensive loss | (26,991) | (17,591) |
| TOTAL COMPREHENSIVE LOSS | $(26,991) | $(17,591) |
| Net loss per share of common stock, basic and diluted | $(21.83) | $(63.24) |
| Weighted-average number of common stock used in net loss per share, basic and diluted | 1,230,698 | 276,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.